Brian Park, PharmD

Drug Information Specialist https://www.medicalbag.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Medicine

Head Lice Treatment Xeglyze Gets FDA Approval

Brian Park, PharmD

August 4, 2020

The FDA has approved Xeglyze™ (abametapir; Dr. Reddy’s Laboratories) for the treatment of head lice infestation in patients aged 6 months and older.

Medicine

Early Data Show Investigational ChAdOx1 nCoV-19 Vaccine Safe, Immunogenic

Brian Park, PharmD

July 28, 2020

Interim results from the phase 1/2 COV001 trial evaluating the vaccine candidate ChAdOx1 nCoV-19 (AZD1222) showed that vaccination led to strong immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in all evaluated participants.

Medicine

Immune Responses Observed in All Participants Dosed With Moderna’s COVID-19 Vaccine Candidate

Brian Park, PharmD

July 17, 2020

Participants demonstrated high levels of neutralizing antibody activity that exceeded those seen in convalescent sera obtained from persons with confirmed COVID-19.

Medicine

US Trial Investigating Sarilumab for COVID-19 Stopped

Brian Park, PharmD

July 14, 2020

A phase 3 trial evaluating sarilumab (Sanofi and Regeneron), an interleukin-6 antagonist, in patients with COVID-19 requiring mechanical ventilation did not meet its primary and key secondary end points.

Medicine

Pfizer, BioNTech’s COVID-19 Vaccine Candidate Looks Promising in Early Human Trial

Brian Park, PharmD

July 7, 2020

Pfizer and BioNTech SE announced positive preliminary results from the phase 1/2 study evaluating the safety, tolerability, and immunogenicity of escalating doses of the vaccine candidate BNT162b1 against COVID-19.

Medicine

Novel Therapy for Alzheimer Disease Agitation Gets Breakthrough Designation

Brian Park, PharmD

July 6, 2020

The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease (AD) agitation.

Medicine

Phase 1 Study of Adjuvanted COVID-19 Vaccine Candidate Begins

Brian Park, PharmD

June 26, 2020

A phase 1 study evaluating the safety, reactogenicity and immunogenicity of SCB-2019, a vaccine candidate for coronavirus disease 2019 (COVID-19), has been initiated by Clover Biopharmaceuticals.

Medicine

New Rapid-Acting Insulin Lispro Approved by FDA

Brian Park, PharmD

June 25, 2020

The FDA has approved Lyumjev™ (insulin lispro-aabc injection; Lilly) to improve glycemic control in adults with type 1 and type 2 diabetes.

Medicine

FDA Approves Long-Acting Insulin Glargine Injection for T1D, T2D

Brian Park, PharmD

June 24, 2020

The FDA has approved Semglee™ (insulin glargine injection; Mylan and Biocon) to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Medicine

FDA Clears Video Game-Based Therapy for Pediatric ADHD

Brian Park, PharmD

June 23, 2020

The FDA has cleared EndeavorRxTM (AKL-T01; Akili Interactive) for use as a prescription-only video game-based digital therapeutic to improve attention function in pediatric patients aged 8-12 years with primarily inattentive or combined-type ADHD.

Next post in Medicine